PepJunkie Home of the Peptonauts
More

Research

Mazdutide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Mazdutide is a dual agonist of the glucagon receptor and the glucagon-like peptide-1 receptor. · pmid:41028652

History

It received its first approval in China in June 2025 for long-term weight management in adults with obesity or overweight, followed in September 2025 by approval for glycaemic control in type 2 diabetes. · pmid:41028652

In a phase 3 trial of 610 Chinese adults with overweight or obesity, body weight fell by about 10% and 12.5% on the two doses at week 32. · pmid:40421736

Identity

PubChem CID 167312357: Mazdutide, C207H317N45O65, 4476 g/mol. · pubchem:167312357

CAS registry number 2259884-03-0. · pubchem:167312357


Where the evidence actually sits

Established100%

Proportion of the 2 claims about Mazdutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.


Living evidence history

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. (2025) · establishedMazdutide: First Approval. (2025) · established20252025

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.


Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Mazdutide yet.


Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · pmid 40421736 · 2025
    • Mazdutide: First Approval. · pmid 41028652 · 2025
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.